pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,910 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1018Endpoints769BioPharma Dive293BioSpace209Fierce Biotech198onclive165raps74globenewswire health73fda recalls
therapy area
allOncology5941Rare Disease1399Cardiology1084Hematology1008Immunology991Pulmonology892Vaccines885Psychiatry & CNS710
  • Trump administration warns against using federal dollars on fentanyl test strips
    The Trump administration underlines a “clear shift away from harm reduction and practices” that it says facilitates illegal drug use.
    STAT · 3mo ago↗ source
  • Utah doctors demand suspension of Doctronic AI program
    Members of Utah’s medical licensing board have called for the suspension of a temporary program allowing a startup to use AI to refill prescription medications. The startup, Doctronic, struck an ag…
    Endpoints · 3mo ago↗ source
  • Oruka surges as long-acting psoriasis drug shows early promise
    A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
    BioPharma Dive · 3mo ago
← prev
page 114 of 117
next →
47
fda medwatch36
fda press28
Ophthalmology419
Endocrinology & Metabolism375
Pain371
Infectious Disease346
↗ source
  • Veradermics soars on positive data for baldness treatment
    The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medica…
    BioPharma Dive · 3mo ago↗ source
  • Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next
    Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous…
    Endpoints · 3mo ago↗ source
  • Thermo Fisher sells microbiology biz; Ligand to buy XOMA
    Thermo Fisher Scientific sells microbiology business: Astorg, a European private equity firm, will acquire the unit for $1.075 billion. Thermo Fisher’s microbiology business is part of its specialt…
    Endpoints · 3mo ago↗ source
  • STAT+: An insider reveals the real goals of prior authorization
    Years ago, Archelle Georgiou helped squash prior auths at one of America's biggest health insurers.
    STAT · 3mo ago↗ source
  • Lilly to buy startup Ajax in bid for a better JAK drug
    Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
    BioPharma Dive · 3mo ago↗ source
  • Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi
    Oruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug…
    Endpoints · 3mo ago↗ source
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
    Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedema
    STAT · 3mo ago↗ source
  • Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
    The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.
    BioPharma Dive · 3mo ago↗ source
  • What’s the true risk for eating disorders with GLP-1s?
    The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning Rounds
    STAT · 3mo ago↗ source
  • Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
    Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as
    Endpoints · 3mo ago↗ source
  • Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial
    A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the inve…
    Endpoints · 3mo ago↗ source
  • Intellia's in vivo CRISPR therapy first to succeed in Phase 3
    An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approv…
    Endpoints · 3mo ago↗ source
  • STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
    With good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?
    STAT · 3mo ago↗ source
  • Veradermics wins at growing hair with oral Rogaine in first key test as a public company
    Veradermics has succeeded in its first major test as a newly-minted public company. The biotech's form of oral Rogaine cleared the bar in a Phase 2/3 trial in men with mild-to-moderate pattern hair…
    Endpoints · 3mo ago↗ source
  • AI biotech Fathom raises $47M Series A, renames from Atommap
    In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his eponymous research company. Huafeng…
    Endpoints · 3mo ago↗ source
  • STAT+: Veradermics’ hair loss drug succeeds in late-stage trial
    The company is one of the most advanced players in the hair loss field, which has seen a surge of investor enthusiasm.
    STAT · 3mo ago↗ source
  • STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
    A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.
    STAT · 3mo ago↗ source
  • STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depression
    FDA approved a request from Motif Neurotech, to start an initial feasibility trial to test a brain implant to treat depression.
    STAT · 3mo ago↗ source
  • NIH-funded research lags in reporting sex differences, new study finds
    Fewer than half of papers published by NIH-funded researchers analyze or report their data by sex, a new study found.
    STAT · 3mo ago↗ source
  • Opinion: I’m a fourth-year med student, but I only learned one historical example of medical racism
    Modern randomized controlled trials often rely on marginalized populations abroad.
    STAT · 3mo ago↗ source
  • Opinion: Patients seeking mental health treatment are not commodities
    Legal agreements that directly shape access to care remain invisible to the very people whose lives they govern.
    STAT · 3mo ago↗ source